

Resource Summary Report

Generated by ASWG on Aug 19, 2026

Purified anti-human CD28 (Maxpar(R) Ready)

RRID:AB_2563737

Type: Antibody

Proper Citation

BioLegend Cat# 302937, RRID:AB_2563737

Antibody Information

URL: http://antibodyregistry.org/AB_2563737

Proper Citation: BioLegend Cat# 302937, RRID:AB_2563737

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, CyTOF®

Antibody Name: Purified anti-human CD28 (Maxpar(R) Ready)

Description: This monoclonal targets CD28

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone CD28.2

Antibody ID: AB_2563737

Vendor: BioLegend

Catalog Number: 302937

Record Creation Time: 20250819T232002+0000

Record Last Update: 20250820T050110+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD28 (Maxpar(R) Ready).

No alerts have been found for Purified anti-human CD28 (Maxpar(R) Ready).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Zheng D, et al. (2025) CD4+ anti-TGF- β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects. Cell reports. Medicine, 6(3), 102020.

Wang Q, et al. (2024) Benzosciprin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell reports. Medicine, 5(2), 101357.

Klysz DD, et al. (2024) Inosine induces stemness features in CAR-T cells and enhances potency. Cancer cell, 42(2), 266.

Kaczanowska S, et al. (2024) Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer cell, 42(1), 35.

Yoshikawa T, et al. (2024) Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. Cell reports. Medicine, 5(5), 101526.

Lukhele S, et al. (2022) The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity. Immunity, 55(12), 2369.

Loo Yau H, et al. (2021) DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells. Molecular cell, 81(7), 1469.

van Montfoort N, et al. (2018) NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines. Cell, 175(7), 1744.

Wei SC, et al. (2017) Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, 170(6), 1120.